{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T01:15:23Z","timestamp":1775697323639,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.ymgme.2010.10.012","type":"journal-article","created":{"date-parts":[[2010,10,31]],"date-time":"2010-10-31T08:49:10Z","timestamp":1288514950000},"page":"176-180","source":"Crossref","is-referenced-by-count":23,"title":["Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease"],"prefix":"10.1016","volume":"102","author":[{"given":"Stephen","family":"Zano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhika","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Szucs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reuben","family":"Matalon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald E.","family":"Viola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2010.10.012_bb0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/archneurpsyc.1931.02230020085005","article-title":"Schindler's Encephalitis Periaxialis Diffusa","volume":"25","author":"Canavan","year":"1931","journal-title":"Arch. Neurol. Psychiat."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0010","first-page":"572","article-title":"Sur une idiotie familiale avec degenerescence spongieuse du nevraxe","volume":"49","author":"van Bogaert","year":"1949","journal-title":"Acta Neurosci. Psychiatry Belg."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/ejpn.2001.0467","article-title":"Canavan disease: a review of recent developments","volume":"5","author":"Gordon","year":"2001","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0020","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ajmg.1320290234","article-title":"Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease","volume":"29","author":"Matalon","year":"1988","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0025","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0065-3101(24)00039-2","article-title":"Recent advances in Canavan disease","volume":"46","author":"Matalon","year":"1999","journal-title":"Advis. Pediatr."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0030","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0022-3476(95)70105-2","article-title":"Canavan disease: from spongy degeneration to molecular analysis","volume":"127","author":"Matalon","year":"1995","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0035","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.ejhg.5200477","article-title":"Mutation detection in the aspartoacylase gene in 17 patients with Canavan disease: four new mutations in the non-Jewish population","volume":"8","author":"Sistermans","year":"2000","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0169-328X(95)00044-S","article-title":"N-Acetylaspartate as an acetyl source in the nervous system","volume":"31","author":"Mehta","year":"1995","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0045","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1471-4159.2001.00456.x","article-title":"Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase","volume":"78","author":"Chakraborty","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0050","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00235902","article-title":"Acetyl transport mechanisms. Involvement of N-acetyl aspartic acid in de novo fatty acid biosynthesis in the developing rat brain","volume":"5","author":"D'Adamo","year":"1968","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0055","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1471-4159.1966.tb10292.x","article-title":"Acetate metabolism in the nervous system. N-acetyl-L-aspartic acid and the biosynthesis of brain lipids","volume":"13","author":"D'Adamo","year":"1966","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0060","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/ana.410340606","article-title":"Neuron loss localizes human temporal lobe epilepsy by in vivo proton magnetic resonance","volume":"34","author":"Hugg","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0065","first-page":"1073","article-title":"Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy","volume":"157","author":"Richards","year":"1991","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0070","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0361-9230(93)90269-H","article-title":"Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-acetyl-aspartyl-glutamate in myotrophic lateral sclerosis","volume":"30","author":"Plaitakis","year":"1993","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0075","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1212\/WNL.42.8.1578","article-title":"N-acetyl-l-aspartate and other amino acid metabolites in Alzheimer's disease brain","volume":"42","author":"Klunk","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2010.10.012_bb0080","unstructured":"Freese, A. (1997). Gene Therapy of Canavan Disease, clinical trial 222\u20131997\u201311."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0085","unstructured":"Leone, P. and Simeone, F. A. (2000). Gene Therapy of Canavan Disease using AAV for Brain Gene Transfer, clinical trial 381\u20132000\u201301."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0090","first-page":"249","article-title":"The uses and properties of PEG-linked proteins","volume":"9","author":"Delgado","year":"1992","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ymthe.2003.11.002","article-title":"Toward PKU enzyme replacement therapy: PEGylation with activity retention for three forms of recombinant phenylalanine hydroxylase","volume":"9","author":"Gamez","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymgme.2005.05.012","article-title":"Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria","volume":"86","author":"Wang","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0105","first-page":"349","article-title":"Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency","volume":"3","author":"Booth","year":"2009","journal-title":"Biologics Targets Ther."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/(SICI)1521-2254(200005\/06)2:3<165::AID-JGM107>3.0.CO;2-R","article-title":"Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system","volume":"2","author":"Matalon","year":"2000","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0003-9861(03)00055-9","article-title":"Purification and preliminary characterization of brain aspartoacylase","volume":"413","author":"Moore","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0120","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1073\/pnas.0607817104","article-title":"Structure of aspartoacylase, the brain enzyme impaired in Canavan disease","volume":"104","author":"Bitto","year":"2007","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2010.10.012_bb0125","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1021\/bi702400x","article-title":"Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue","volume":"47","author":"Le Coq","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.ymgme.2010.10.012_bb0130","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/cne.20080","article-title":"Immunohistochemical localization of aspartoacylase in the rat central nervous system","volume":"472","author":"Madhavarao","year":"2004","journal-title":"J. Com. Neurol."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0135","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10545-010-9100-z","article-title":"Metabolic acetate therapy improves phenotype in the tremor rate model of Canavan disease","volume":"33","author":"Arun","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2010.10.012_bb0140","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1021\/bi052608w","article-title":"Characterization of human aspartoacylase: the brain enzyme responsible for Canavan disease","volume":"45","author":"Le Coq","year":"2006","journal-title":"Biochemistry"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719210003719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719210003719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T22:36:03Z","timestamp":1711924563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719210003719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S1096719210003719"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2010.10.012","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}